Huber M, Huber B. Innovation in oncology drug development. J Oncol. 2019;2019:9683016. https://doi.org/10.1155/2019/9683016.
Article CAS PubMed PubMed Central Google Scholar
Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9:465–72. https://doi.org/10.1001/jamaoncol.2022.7826.
Article PubMed PubMed Central Google Scholar
Kim H, Goodall S, Liew D. Health technology assessment challenges in oncology: 20 years of value in health. Value Health. 2019;22:593–600. https://doi.org/10.1016/j.jval.2019.01.001.
Winn AN, Ekwueme DU, Guy GP Jr, Neumann PJ. Cost-utility analysis of cancer prevention, treatment, and control: a systematic review. Am J Prev Med. 2016;50:241–8. https://doi.org/10.1016/j.amepre.2015.08.009.
Higgins AM, Harris AH. Health economic methods: cost-minimization, cost-effectiveness, cost-utility, and cost-benefit evaluations. Crit Care Clin. 2012;28(11–24):v. https://doi.org/10.1016/j.ccc.2011.10.002.
Robinson R. Cost-utility analysis. BMJ. 1993;307:859–62. https://doi.org/10.1136/bmj.307.6908.859.
Article CAS PubMed PubMed Central Google Scholar
Roudijk B, Donders ART, Stalmeier PFM. Setting dead at zero: applying scale properties to the QALY model. Med Decis Making. 2018;38:627–34. https://doi.org/10.1177/0272989X18765184.
Article PubMed PubMed Central Google Scholar
Rowen D, Azzabi Zouraq I, Chevrou-Severac H, van Hout B. International regulations and recommendations for utility data for health technology assessment. Pharmacoeconomics. 2017;35:11–9. https://doi.org/10.1007/s40273-017-0544-y.
Haute Autorité de Santé. Indicateurs pour l'amélioration de la qualité et de la sécurité des soins: aide à l’utilisation de questionnaires patients de mesure des résultats de soins dans le cadre de l’expérimentation « Episode de soins ». Paris; September 2019.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36. https://doi.org/10.1007/s11136-011-9903-x.
Article CAS PubMed PubMed Central Google Scholar
Ware JE, Jr. SF-36 Health survey: manual and interpretation guide. Boston; 1993.
Brazier J, Ara R, Rowen D, Chevrou-Severac H. A review of generic preference-based measures for use in cost-effectiveness models. Pharmacoeconomics. 2017;35:21–31. https://doi.org/10.1007/s40273-017-0545-x.
Gibson AEJ, Longworth L, Bennett B, Pickard AS, Shaw JW. Assessing the content validity of preference-based measures in cancer. Value Health. 2024;27:70–8. https://doi.org/10.1016/j.jval.2023.10.006.
Noel CW, Keshavarzi S, Forner D, Stephens RF, Watson E, Monteiro E, et al. Construct validity of the EuroQoL-5 dimension and the health utilities index in head and neck cancer. Otolaryngol Head Neck Surg. 2022;166:877–85. https://doi.org/10.1177/01945998211030173.
van Dongen-Leunis A, Redekop WK, Uyl-de Groot CA. Which questionnaire should be used to measure quality-of-life utilities in patients with acute leukemia? An evaluation of the validity and interpretability of the EQ-5D-5L and preference-based questionnaires derived from the EORTC QLQ-C30. Value Health. 2016;19:834–43. https://doi.org/10.1016/j.jval.2016.05.008.
King MT, Costa DSJ, Aaronson NK, Brazier JE, Cella DF, Fayers PM, et al. QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30. Qual Life Res. 2016;25:625–36. https://doi.org/10.1007/s11136-015-1217-y.
Article CAS PubMed Google Scholar
King MT, Viney R, Simon Pickard A, Rowen D, Aaronson NK, Brazier JE, et al. Australian utility weights for the EORTC QLU-C10D, a multi-attribute utility instrument derived from the cancer-specific quality of life questionnaire, EORTC QLQ-C30. Pharmacoeconomics. 2018;36:225–38. https://doi.org/10.1007/s40273-017-0582-5.
Norman R, Kemmler G, Viney R, Pickard AS, Gamper E, Holzner B, et al. Order of presentation of dimensions does not systematically bias utility weights from a discrete choice experiment. Value Health. 2016;19:1033–8. https://doi.org/10.1016/j.jval.2016.07.003.
Gamper E-M, Holzner B, King MT, Norman R, Viney R, Nerich V, Kemmler G. Test-retest reliability of discrete choice experiment for valuations of QLU-C10D health states. Value Health. 2018;21:958–66. https://doi.org/10.1016/j.jval.2017.11.012.
Gamper E-M, King MT, Norman R, Loth FLC, Holzner B, Kemmler G. The EORTC QLU-C10D discrete choice experiment for cancer patients: a first step towards patient utility weights. J Patient Rep Outcomes. 2022;6:42. https://doi.org/10.1186/s41687-022-00430-5.
Article PubMed PubMed Central Google Scholar
Seyringer S, Pilz MJ, Jansen F, Büttner M, King MT, Norman R, et al. Cancer-specific utility instrument for health economic evaluations: a synopsis of the EORTC QLU-C10D user manual and current validity evidence. Eur J Cancer. 2025;217: 115235. https://doi.org/10.1016/j.ejca.2025.115235.
Giesinger JM, Efficace F, Aaronson N, Calvert M, Kyte D, Cottone F, et al. Past and current practice of patient-reported outcome measurement in randomized cancer clinical trials: a systematic review. Value Health. 2021;24:585–91. https://doi.org/10.1016/j.jval.2020.11.004.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76. https://doi.org/10.1093/jnci/85.5.365.
Article CAS PubMed Google Scholar
Gamper EM, King MT, Norman R, Efficace F, Cottone F, Holzner B, Kemmler G. EORTC QLU-C10D value sets for Austria, Italy, and Poland. Qual Life Res. 2020;29:2485–95. https://doi.org/10.1007/s11136-020-02536-z.
Article CAS PubMed PubMed Central Google Scholar
Jansen F, Verdonck-de Leeuw IM, Gamper E, Norman R, Holzner B, King M, Kemmler G. Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D. Qual Life Res. 2021;30:2009–19. https://doi.org/10.1007/s11136-021-02767-8.
Article PubMed PubMed Central Google Scholar
Kemmler G, Gamper E, Nerich V, Norman R, Viney R, Holzner B, King M. German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30. Qual Life Res. 2019;28:3197–211. https://doi.org/10.1007/s11136-019-02283-w.
Article PubMed PubMed Central Google Scholar
McTaggart-Cowan H, King MT, Norman R, Costa DSJ, Pickard AS, Regier DA, et al. The EORTC QLU-C10D: the Canadian valuation study and algorithm to derive cancer-specific utilities from the EORTC QLQ-C30. MDM Policy Pract. 2019;4:2381468319842532. https://doi.org/10.1177/2381468319842532.
Article PubMed PubMed Central Google Scholar
Nerich V, Gamper EM, Norman R, King M, Holzner B, Viney R, Kemmler G. French value-set of the QLU-C10D, a cancer-specific utility measure derived from the QLQ-C30. Appl Health Econ Health Policy. 2021;19:191–202. https://doi.org/10.1007/s40258-020-00598-1.
Norman R, Mercieca-Bebber R, Rowen D, Brazier JE, Cella D, Pickard AS, et al. U.K. utility weights for the EORTC QLU-C10D. Health Econ. 2019;28:1385–401. https://doi.org/10.1002/hec.3950.
Revicki DA, King MT, Viney R, Pickard AS, Mercieca-Bebber R, Shaw JW, et al. United States utility algorithm for the EORTC QLU-C10D, a multiattribute utility instrument based on a cancer-specific quality-of-life instrument. Med Decis Making. 2021;41:485–501. https://doi.org/10.1177/0272989X211003569.
Comments (0)